Home > Rheumatology > ACR 2019 > Spotlight on Rheumatoid Arthritis > Sustained efficacy of monotherapy with upadacitinib after 48 weeks

Sustained efficacy of monotherapy with upadacitinib after 48 weeks

Presented By
Prof. Joseph Smolen, Medical University of Vienna, Austria
Conference
ACR 2019
Trial
SELECT-MONOTHERAPY
In the extension period of the SELECT-MONOTHERAPY trial, clinical and functional outcomes continued to improve in rheumatoid arthritis (RA) patients treated with the Janus kinase (JAK)1 inhibitor upadacitinib [1]. Monotherapy with the oral JAK1-selective inhibitor upadacitinib was assessed over 14 weeks in patients with RA with an inadequate response to methotrexate in the SELECT-MONOTHERAPY trial. In this trial, therapy with upadacitinib showed statistically significant improvements in clinical and functional outcomes versus continuing methotrexate. The safety profile was similar to previous upadacitinib studies, when the JAK1 inhibitor was given together with methotrexate [2]. To further evaluate the efficacy and safety of monotherapy with upadacitinib, a long-term extension period of SELECT-MONOTHERAPY was performed. In the double-blind period, patients on stable methotrexate were randomised to either continue methotrexate or switch to once-daily...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on